A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Phase 2

Completed

• Conditions: Neoplasms
• Interventions: Drug: Vemurafenib

• Registration Number: NCT01286753
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This open-label, multi-center study will evaluate the safety and efficacy of Vemurafenib (RO5185426) in participants with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine therapy. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until progressive disease or unacceptable toxicity occurs.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-01-28
• Study First Submitted QC: 2011-01-28
• Study First Posted: 2011-01-31
• Study Start: 2011-06
• Primary Completion: 2014-11
• Study Completion: 2015-05
• Status Verified: 2016-07
• Results First Submitted: 2016-07-22
• Results First Submitted QC: 2016-07-22
• Last Update Submitted: 2016-07-22
• Results First Posted: 2016-09-07
• Last Update Posted: 2016-09-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

• Adult participants. >/= 18 years of age
• Histologically confirmed metastatic or unresectable papillary thyroid cancer for which standard curative or palliative measures do not exist or are no longer effective; participants whose tumors exhibit areas of "other histology" may be enrolled, provided the tumor histology remains predominantly papillary
• Positive for BRAF V600 mutation (Roche Cobas 4800 BRAF V600 Mutation Test)
• Radioactive Iodine resistant disease
• Prior therapy excluding (Cohort 1, TKI Naive) or including (Cohort 2, TKI Experienced) TKI
• Clinically relevant disease progression according to RECIST criteria within the prior 14 months
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Adequate hematological, renal and liver function

Exclusion Criteria

• Histological diagnosis other than papillary PTC, including squamous cell variants of PTC or PTC with areas of squamous metaplasia
• Active or untreated central nervous system metastases
• History of or known carcinomatous meningitis
• Anticipated or ongoing administration of any anti-cancer therapies other than those administered in the study
• Active squamous cell skin cancer that has not been excised or adequately healed post excision
• Previous treatment with any agent that specifically and selectively targets the MEK or BRAF pathway
• Prior radiotherapy to the only measurable lesion
• Clinically relevant cardio-vascular disease or event within the prior 6 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Tyrosine Kinase Inhibitor (TKI) Naive	Vemurafenib	Vemurafenib in participants naive to any prior systemic TKI therapy.
TKI Experienced	Vemurafenib	Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).

Primary Outcome Measures

Name	Time	Method
Best Overall Response Rate in TKI-Naive Participants	Up to approximately 4 years	Best overall response rate was assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Best overall response rate: the percentage of participants with best objective response of complete response (CR) or partial response (PR) (calculated as the number of participants with best response CR or PR divided by the total number of efficacy-evaluable participants). CR: disappearance of all target lesions with reduction in target/non-target pathological lymph nodes to \< 10 millimeters (mm). PR: ≥ 30% decrease in the sum of diameters of target lesions, compared to the baseline sum diameters.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Adverse Events	Baseline until 28 days after the last dose of study treatment or until initiation of another anti-cancer therapy, whichever occurred first (up to approximately 4 years)	An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Best Overall Response Rate in TKI-Experienced Participants	Up to approximately 4 years	Best overall response rate was assessed by the investigators according to RECIST v1.1. Best overall response rate: the percentage of participants with best objective response of CR or PR (calculated as the number of participants with best response CR or PR divided by the total number of efficacy-evaluable participants). CR: disappearance of all target lesions with reduction in target/non-target pathological lymph nodes to \< 10 mm. PR: ≥ 30% decrease in the sum of diameters of target lesions, compared to the baseline sum diameters.
Duration of Response	From the date of first qualifying response to the date of PD or death for any cause (up to approximately 4 years)	Duration of response (for participants with confirmed best response CR or PR): the interval between earliest qualifying response and date of progression of disease (PD) or death for any cause, whichever occurred first; participants with no documented progression after CR or PR were censored at the date of last known CR or PR, respectively. CR: disappearance of all target lesions with reduction in target/non-target pathological lymph nodes to \< 10 mm. PR: ≥ 30% decrease in the sum of diameters of target lesions, compared to the baseline sum diameters. PD: ≥ 20% increase in the sum of diameters of target lesions, compared to the smallest sum on study.
Progression-Free Survival	From the day of first treatment until the first documented PD or death (up to approximately 4 years)	Progression-free survival: the interval between the day of first treatment and the first documentation of PD or death; participants who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression-free; participants without post baseline tumor assessments were censored at the time of enrollment. PD: ≥ 20% increase in the sum of diameters of target lesions, compared to the smallest sum on study.
Clinical Benefit Rate	Up to approximately 4 years	Clinical benefit rate: the percentage of participants with confirmed CR, PR, or stable disease (SD; maintained for at least 6 months) as assessed by investigators according to RECIST v1.1. CR: disappearance of all target lesions with reduction in target/non-target pathological lymph nodes to \< 10 mm. PR: ≥ 30% decrease in the sum of diameters of target lesions, compared to the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, compared to the baseline sum diameters.
Overall Survival	From the date of first treatment to the date of death for any cause (up to approximately 4 years)	Overall survival: the interval between the date of first treatment to the date of death, regardless of the cause of death; participants who were alive at the time of the analysis were censored at the date of the last known alive; participants with no post baseline information were censored at the time of enrollment.
Pharmacokinetics of Vemurafenib: Area Under the Concentration-Time Curve (AUC)	Up to approximately 4 years	AUC is a measure of the drug or biologic concentration in the body following administration.